Metagenomi Therapeutics (MGX) Liabilities and Shareholders Equity (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $197.0 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $197.0 million, down 33.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $938.3 million (down 31.35% YoY), and the FY2025 annual result was $221.1 million, down 31.88% from the prior year.
• Liabilities and Shareholders Equity eased to $197.0 million in Q1 2026 per MGX's latest filing, from $221.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $415.4 million in Q1 2024 and troughed at $197.0 million in Q1 2026.
• A 4-year average of $308.5 million and a median of $311.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity declined 11.03% in 2024, then slumped 33.88% in 2026.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $364.8 million in 2023, then dropped by 11.03% to $324.6 million in 2024, then sank by 31.88% to $221.1 million in 2025, then fell by 10.92% to $197.0 million in 2026.
• Business Quant data shows MGX's Liabilities and Shareholders Equity at $197.0 million in Q1 2026, $221.1 million in Q4 2025, and $247.9 million in Q3 2025.